Evidence map›Paper›PMID 40508118›Full record

ArticleInternational journal of molecular sciences2025

Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.

Martino Pedrani, Giuseppe Salfi, Sara Merler, Irene Testi, Chiara Maria Agrippina Clerici, Giovanna Pecoraro, Luis Castelo-Branco, Fabio Turco, Luigi Tortola, Ursula Vogl and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Martino PedraniOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.ORCID 0000-0002-8502-8226
Giuseppe SalfiOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.ORCID 0000-0003-4953-0339
Sara MerlerOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Irene TestiOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Chiara Maria Agrippina ClericiOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Giovanna PecoraroOncology Department, University of Naples "Federico II", 80131 Naples, Italy.ORCID 0009-0003-6743-6933
Luis Castelo-BrancoOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Fabio TurcoOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Luigi TortolaOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Ursula VoglOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.ORCID 0000-0002-2046-4246
Silke GillessenOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Jean-Philippe TheurillatInstitute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
Thomas ZilliFaculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.ORCID 0000-0002-4784-9883
Ricardo Pereira MestreOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.ORCID 0000-0002-3123-3697

Funding

This study was supported by funding from Fondazione Daccò (Fondo EOC-USI). Fondazione Daccò (Fondo EOC-USI).
6 · The paper itself

Abstract

Alterations in aggressive-variant prostate cancer-associated tumor suppressor genes (AVPC-TSG:

Indexed as

Androgen Receptor AntagonistsGenes, Tumor SuppressorProstatic NeoplasmsReceptors, AndrogenAgedAged, 80 and overBiomarkers, TumorHumansMaleMiddle AgedPrognosisProgression-Free SurvivalPTEN PhosphohydrolaseRetinoblastoma Binding ProteinsRetrospective StudiesSignal TransductionAndrogen Receptor AntagonistsAR protein, humanBiomarkers, TumorPTEN PhosphohydrolasePTEN protein, humanRB1 protein, humanReceptors, AndrogenRetinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein Ligasesaggressive-variant prostate cancerandrogen receptor pathway inhibitorspredictiveprognosticprostate cancerPTEN/PI3K/AKTRB1survivalTP53tumor suppressor genes

Identifiers

PMID40508118
PMCPMC12154572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.